Oncology Peer Review On-The-Go: Utility of 21-Gene Recurrence Score for Node-Positive Breast Cancer

Podcast

CancerNetwork®’s podcast dissected a review article published in the journal ONCOLOGY® on the 21-gene recurrence score in patients with node-positive breast cancer.

This week, CancerNetwork® examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.”

The piece highlights the existing literature regarding the prognostic and predictive capabilities of the Oncotype Dx 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature.

For the summary, CancerNetwork® spoke with 2 authors of the review, Alison Laws, MD, an associate surgeon at the Brigham and Women’s Hospital, and Philip Poorvu, MD, a medical oncologist at the Dana-Farber Cancer Institute. Laws and Poorvu provided valuable information on the process, focus, and main takeaways of this review.

For the article’s response perspective, we spoke with Sara Hurvitz, MD, a professor of medicine at the UCLA Johnson Comprehensive Cancer Center. Hurvitz detailed a number of studies analyzed in the review article, putting into perspective the findings from various pieces of literature. She expanded on the team’s work and looked toward the future for treating patients with node-positive breast cancer.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content